Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantly

Journal of Virology

Volumn 76, Issue 17, 2002, Pages 8659-8666

  Resch, Wolfgang ^a   Ziermann, Rainer ^a   Parkin, Neil ^a   Gamarnik, Andrea ^a   Swanstrom, Ronald ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; GAG PROTEIN; NELFINAVIR; PROTEINASE INHIBITOR;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CALCULATION; EVOLUTION; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; VIROGENESIS; VIRUS INFECTIVITY; VIRUS REPLICATION;

CARBAMATES; CELL LINE; COCULTURE TECHNIQUES; DRUG RESISTANCE, VIRAL; GENE PRODUCTS, GAG; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MUTATION; NELFINAVIR; PROTEIN PRECURSORS; SULFONAMIDES; VIRUS REPLICATION;

EID: 0036337934     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.17.8659-8666.2002     Document Type: Article

References (40)

1. Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1
2. Characterization of an HIV-1 isolate displaying an apparent absence of virion-associated reverse transcriptase activity
3. HIV drug resistance and viral fitness
4. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir
5. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors
6. Effects of human immunodeficiency virus type 1 resistance to protease inhibitors on reverse transcriptase processing, activity, and drug sensitivity
7. Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations
8. Quantitation of human immunodeficiency virus type 1 infection kinetics
9. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632
10. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
11. 2-symmetric protease inhibitor
12. Quantitation of relative fitness and great adaptability of clonal populations of RNA viruses
13. Virological and immunological characteristics of HIV treatment failure
14. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated β-galactosidase gene
15. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays
16. In vivo sequence diversity of the protease of human immunodeficiency virus type 1: Presence of protease inhibitor-resistant variants in untreated subjects
17. Structural and kinetic analysis of drug resistant mutants of HIV-1 protease
18. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: Phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients
19. Estimating relative fitness in viral competition experiments
20. Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants
21. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1
22. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy
23. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir
24. Decay characteristics of HIV-1-infected compartments during combination therapy
25. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1
26. Altered viral fitness of HIV-1 following failure of protease inhibitor-based therapy
27. Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity
28. A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression
29. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis
30. Population dynamics studies of wild-type and drug-resistant mutant HIV in mixed infections
31. A multiple-site-specific heteroduplex tracking assay as a tool for the study of viral population dynamics
32. HIV type 1 protease cleavage site mutations and viral fitness: Implications for drug susceptibility phenotyping assays
33. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa
34. Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity
35. Human immunodeficiency virus reverse transcriptase and protease sequence database
36. A mutation in human immunodeficiency virus type 1 protease at position 88, located outside the active site, confers resistance to the hydroxyethylurea inhibitor SC-55389A
37. Estimate of the frequency of human immunodeficiency virus type 1 protease inhibitor resistance within unselected virus populations in vitro
38. Viral dynamics in human immunodeficiency virus type 1 infection
39. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo
40. A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity